Pub. Date : 2014 Dec
PMID : 25474278
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | The post-progression survival (PPS) of p53-positive patients undergoing 2nd and/or 3rd line chemotherapy with irinotecan and/or cetuximab was significantly longer compared to p53-negative patients. | Irinotecan | tumor protein p53 | Homo sapiens |
2 | mCRC patients with p53 overexpression undergoing an irinotecan containing second- or third-line chemotherapy after oxaliplatin failure have a significantly longer post-progression survival compared to patients without p53 overexpression. | Irinotecan | tumor protein p53 | Homo sapiens |
3 | To validate the clinical impact of p53 in patients with mCRC treated with irinotecan- and/or cetuximab further studies are needed. | Irinotecan | tumor protein p53 | Homo sapiens |